The shift away from paper-based systems has brought numerous companies into the eClinical market, in which Medidata and Phase Forward are the major players, and Kika is hoping the revisions will strengthen its position in the competitive sector.
Linda Beneze, CEO of Kika, believes Veracity offers clients “the most comprehensive platform to protect, control and maximise all of their clinical data” and that version 3.7 is “another important step” in its development.
By modifying the system Kika believes it has improved visibility of existing data at all levels. This is achieved displaying data status from the case level to the data point. Furthermore, monitors and clinical research associates (CRA) can now record and share their activity on a page level.
Kika has also updated Veracity to help monitors review and track pending inconsistencies by allowing authorised users to apply status to edit checks that are flagged automatically by the system.
These changes are accompanied by technical revisions to ensure the system supports recent versions of Internet Explorer and Firefox. Kika has also installed a new navigation tree that gives users the option to allow the system to decide the next relevant element page to be displayed.
By adding these features Kika believes the system goes “well beyond traditional EDC”. The new additional build on the web-based platform that is designed to allow all clinical trial stakeholders to collect, monitor, adjudicate, analyse and manage data in real time.
Shift from devices
In an overview of Kika Crystal Research Associates described how the eClinical company is modifying its EDC system to increase usage by pharma, biotech and contract research organisations (CRO).
Traditionally Kika’s core user base has been medical device companies, including Medtronic, Cordis and Abbott Vascular Devices, but it is increasingly gaining clients in different areas.
In part this shift has been brought about by revisions to Veracity, with the report commenting that version 3.6 was enhanced to meet the specific needs of biotechs.
The complete report can be found here.